Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.

British journal of clinical pharmacology - 1 Dec 2008

Kalliokoski Annikka, Neuvonen Mikko, Neuvonen Pertti J, Niemi Mikko

Abstract excerpt

AIMS: To establish whether the effect of SLCO1B1[encoding organic anion transporting polypeptide 1B1 (OATP1B1)] c.521T-->C (p.Val174Ala) polymorphism on the pharmacokinetics of repaglinide is dose-dependent. METHODS: Twelve healthy volunteers with the SLCO1B1 c.521TT genotype (controls) and eight with the c.521CC genotype ingested a single 0.25-, 0.5-, 1- or 2-mg dose of repaglinide in a dose-escalation study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Blood Glucose
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Liver-Specific Organic Anion Transporter 1

Share to Metabolic Clearance Rate

Share to Organic Anion Transporters

Share to Piperidines

Source

Open in PubMed Open full text

Identifiers

PMID: 18823304
DOI: 10.1111/j.1365-2125.2008.03287.x
PMCID: PMC2675779

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.PMID 18823304Read ↗

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Semantic proximity Read ↗

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.Semantic proximity Read ↗

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Semantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.Semantic proximity Read ↗

The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.Semantic proximity Read ↗

Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Semantic proximity Read ↗

CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.Semantic proximity Read ↗

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.Semantic proximity Read ↗

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.